Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and Janus kinase 3 (JAK3) (JAK1/JAK2/JAK3)

The Janus kinase (JAK) family, specifically JAK1, JAK2, and JAK3, consists of intracellular non-receptor tyrosine kinases that are pivotal in the JAK-STAT signaling pathway (UniProt P23458, O60674, P52333). These enzymes are associated with the cytoplasmic domains of various cytokine receptors and are activated upon ligand binding to the receptor (StatPearls, "Janus Kinase Inhibitors"). Once activated, they phosphorylate Signal Transducers and Activators of Transcription (STAT) proteins, which then dimerize and move into the nucleus to regulate the transcription of genes involved in immune cell function and hematopoiesis (PubMed PMC4843815). Dysregulation of these kinases is linked to several inflammatory and autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis (NIH, "JAK-STAT Signaling"). Drugs such as tofacitinib are designed to inhibit these kinases by competing for the ATP-binding site, thereby reducing the production of pro-inflammatory mediators (PubChem CID 11269418). Clinical use of these inhibitors requires monitoring for side effects such as serious infections, cytopenias, and potential cardiovascular or thrombotic events (FDA, Xeljanz Label). The specific mention of midazolam in the context of these targets typically refers to clinical pharmacology studies demonstrating that tofacitinib does not clinically affect the metabolism of CYP3A4 substrates like midazolam (FDA, Xeljanz Label).

Other names

JAK1JAK2JAK3Janus kinase 1Janus kinase 2Janus kinase 3JAK familyJust Another Kinase

ATP-competitive inhibition of Janus kinases (JAK1, JAK2, JAK3), preventing the phosphorylation of STAT proteins and blocking downstream cytokine signaling.